Results 91 to 100 of about 2,755,308 (302)

A novel quinazolinone insulin receptor inhibitor and its synergy with an EGFR inhibitor in glucose‐driven glioblastoma

open access: yesMolecular Oncology, EarlyView.
The novel styrylquinazolinone‐based molecule W1B effectively suppresses glioblastoma by inhibiting IGF1R and EGFR. In high‐glucose microenvironments driving tumor resistance, W1B acts synergistically with the EGFR inhibitor dacomitinib. This combination safely blocks compensatory survival signaling in zebrafish xenograft models. Showcasing promising in
Patryk Rurka   +9 more
wiley   +1 more source

Australian Broadcasting Authority: annual report 1999-2000

open access: yes, 2000
Annual report of the Commonwealth of Australia communications and broadcasting regulatory authority: the Australian Broadcasting ...
Australian Broadcasting Authority
core  

Patient therapy outcome modeling in cancer organoids is improved by cancer‐associated fibroblasts and organoid assembly convolution

open access: yesMolecular Oncology, EarlyView.
Patient‐derived organoids (PDOs) from pancreatic, colorectal, and gastric cancers were used to evaluate standard and experimental therapies. Incorporating cancer‐associated fibroblasts (CAFs) into organoid cultures improved patient therapy outcome prediction.
Marcin Grochowski   +12 more
wiley   +1 more source

Australian Broadcasting Authority: annual report 1998-1999

open access: yes, 1999
Annual report of the Commonwealth of Australia communications and broadcasting regulatory authority: the Australian Broadcasting ...
Australian Broadcasting Authority
core  

Epigenetic heterogeneity and plasticity in therapy‐induced tumor states through single‐cell multi‐omics

open access: yesMolecular Oncology, EarlyView.
Single‐cell multi‐omics reveals epigenetic heterogeneity across therapy‐adaptive tumor states, including quiescent/dormant, drug‐tolerant persister, and EMT‐like phenotypes. By linking regulatory features with state‐associated biomarkers, these approaches inform biomarker‐guided therapeutic strategies for evolving tumors.
Hee Jung Kim   +3 more
wiley   +1 more source

Optimal Community Energy Storage System Operation in a Multi-Power Consumer System: A Stackelberg Game Theory Approach

open access: yesEnergies
The proliferation of community energy storage systems (CESSs) necessitates effective energy management to address financial concerns. This paper presents an efficient energy management scheme for heterogeneous power consumers by analyzing various cost ...
Gyeong Ho Lee   +3 more
doaj   +1 more source

Australian Broadcasting Authority: annual report 2005-2006

open access: yes, 2006
Annual report of the Commonwealth of Australia communications and broadcasting regulatory authority: the Australian Broadcasting ...
Australian Broadcasting Authority
core  

PAK1 activation drives divergent resistance mechanisms to aromatase inhibition and tamoxifen in a luminal: A breast cancer model

open access: yesMolecular Oncology, EarlyView.
Breast cancer remains a major cause of cancer death in women, frequently developing endocrine therapy resistance. This study demonstrates that upregulated p21‐activated kinase 1 (PAK1) activity drives resistance to tamoxifen and long‐term estrogen deprivation in ER+ breast cancer models.
Luisa Schwarzmüller   +10 more
wiley   +1 more source

Australian Broadcasting Authority: annual report 1994-1995

open access: yes, 1995
Annual report of the Commonwealth of Australia communications and broadcasting regulatory authority: the Australian Broadcasting ...
Australian Broadcasting Authority
core  

Mycobacterial cell division arrest and smooth‐to‐rough envelope transition using CRISPRi‐mediated genetic repression systems

open access: yesFEBS Open Bio, EarlyView.
CRISPRI‐mediated gene silencing and phenotypic exploration in nontuberculous mycobacteria. In this Research Protocol, we describe approaches to control, monitor, and quantitatively assess CRISPRI‐mediated gene silencing in M. smegmatis and M. abscessus model organisms.
Vanessa Point   +7 more
wiley   +1 more source

Home - About - Disclaimer - Privacy